43 results about "Thyroid cancer cell" patented technology

Disclosed herein are novel approaches to thyroid cancer therapy. These approaches include methods to enhance thyroid specific gene expression, for example methods to enhance expression of thyroglobulin and / or the Na<+> / I<-> symporter in thyroid cancer cells. Enhanced expression of thyroid-specific genes promotes cellular differentiation and reduces biologically aggressive behavior such as invasion and metastasis. In addition, enhanced expression of thyroglobulin and / or the Na<+> / I<31 > symporter increases the ability of thyroid cancer cells to concentrate iodine or iodide, thereby making the cells more susceptible to radioactive iodine therapy. Also disclosed herein are methods for detecting thyroid neoplasms in a subject, by administering a therapeutically effective amount of a histone deacetylase inhibitor, administering a detectable agent whose uptake or concentration in thyroid cells is increased by administration of the histone deacetylase inhibitor, and detecting the detectable agent.

A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. The compounds' ability to inhibit RET kinase is quantified, i.e., their respective RET IC50 and EC50 values are described. One such compound, known as cyclobenzaprine and herein as SW-01, has been identified as RET-specific with an IC50 of 300 nM. SW-01 inhibits RET autophosphorylation and blocks the growth and transformation of thyroid cancer cell lines. It has been further tested in pancreatic cancer, breast cancer, and SCLC cell lines. The compounds show utility for inhibition of survival and proliferation of tumour cells.

We examined IQGAP1 copy gain and its relationship with clinicopathologic outcomes of thyroid cancer and investigated its role in cell invasion and molecules involved in the process. We found IQGAP1 copy number (CN) gain ?3 in 1 of 30 (3%) of benign thyroid tumor, 24 of 74 (32%) follicular variant papillary thyroid cancer (FVPTC), 44 of 107 (41%) follicular thyroid cancer (FTC), 8 of 16 (50%) tall cell papillary thyroid cancer (PTC), and 27 of 41 (66%) anaplastic thyroid cancer, in increasing order of invasiveness of these tumors. A similar tumor distribution trend of CN ?4 was also seen. IQGAP1 copy gain was positively correlated with IQGAP1 protein expression. It was significantly associated with extrathyroidal and vascular invasion of FVPTC and FTC and, remarkably, a 50%-60% rate of multifocality and recurrence of BRAF mutation-positive PTC (P=0.01 and 0.02, respectively). The siRNA knock-down of IQGAP1 dramatically inhibited thyroid cancer cell invasion and colony formation. Co-immunoprecipitation assay showed direct interaction of IQGAP1 with E-cadherin, a known invasion-suppressing molecule, which was upregulated when IQGAP1 was knocked down. IQGAP1, through genetic copy gain, plays an important role in the invasiveness of thyroid cancer and represents a useful prognostic marker and therapeutic target for this and other cancers.

The invention relates to the preparation of 131I-thyroid stimulating hormone (TSH) and an application thereof, belonging to the field of radionuclide therapeutic drugs. The compound 131I-thyroid stimulating hormone is a radioiodine marker for thyroid stimulating hormone with pathoclisis in vivo acting on thyrocyte. A preparation method of the 131I-thyroid stimulating hormone comprises the following steps of: carrying out iodine 131 marking on the thyroid stimulating hormone by utilizing a chloramine-T method, a peroxide oxidation method or an iodogen method, and introducing radionuclide iodine 131 for treatment into tyrosine residues in thyroid stimulating hormone molecules. The marking rate of the prepared 131I-TSH is 85.9 percent, the radiochemical purity after purification achieves more than 90 percent, and the prepared 131I-TSH can be stored stably for more than one week at room temperature; the 131I-TSH is mainly metabolized through the liver and excreted through the kidneys; the percentage of ID / g of the 131I-TSH in the thyroid gland is not obviously reduced in four hours; and the 131I-TSH can be concentrated in thyroid gland issues sealed by an iodine solution. Concerning low / undifferentiated thyroid tumours incapable of iodine uptake, the 131I-TSH can increase the radioiodine uptake of thyroid gland cancer cells, and the radioiodine 131 can be chosen for treatment.

The invention discloses a traditional Chinese medicine preparation for treating thyroid cancer, and belongs to the technical field of medicines for treating thyroid cancer. The traditional Chinese medicine preparation is prepared from wolfiporia extensa, codonopsis pilosula, loranthus parasiticus, lentinus edodes, red beans, the root bark of white mulberry, the bark of eucommia, akebiaquinata, lignum dalbergiae odoriferae, bighead atractylodes rhizome, fiveleaf akebia fruits, arisacma consanguineum, pawpaw, hairyvein agrimony, semen coicis, garden burnet, cynanchum glaucescens, Chinese lobelia, folium cycas, hedyotis diffusa, indigo naturalis, cinnamon, subprostrate sophora, polygala tenuifolia, rhizoma alismatis, honeysuckle, panax notoginseng, peach kernels, centipedes and a Chinese starjasmine stem. The traditional Chinese medicine preparation is obtained through reasonable and scientific compatibility of the Chinese herbal medicines, the medicine effects complement each other and directly reach the focus depth place, transfer and spreading of thyroid cancer cells are effectively controlled, meanwhile, the immunologic function of the human body can be enhanced, growth of cancer cells is restrained, and no toxic or side effect is produced; lumps can be reduced within a short period of time, transfer is controlled, pain is relieved, the illness state is stabilized, the life time is prolonged, and clinical cure is achieved; the medicine property is gentle, and the traditional Chinese medicine preparation is gentle, and easy and convenient to take.

The invention relates to a gene relevant to papillary thyroid tumors and an application thereof. According to the base sequence of the gene, real-time and quantitative PCR (Polymerase Chain Reaction) primers are designed and synthesized; the expression level of long-chain non-coding RNA (Ribonucleic Acid) transcribed by the gene is detected in a papillary thyroid carcinoma clinical case specimen; the result shows remarkable reducing of the expression level of the long-chain non-coding RNA in papillary thyroid tumor tissues and the long-chain non-coding RNA of the gene silencing can remarkably promote the growth of thyroid cancer cells. The gene relevant to the papillary thyroid tumors is expected to prepare preparations used in papillary thyroid carcinoma auxiliary diagnosis, gene therapy, curative effect prediction or prognosis.

The invention discloses an application of curcumin in the preparation of a thyroid carcinoma therapeutic agent, and belongs to the technical field of curcumin pharmaceutical application. Curcumin can kill thyroid carcinoma cells specifically and has little influence on normal thyroid cells. Curcumin can promote the apoptosis of thyroid carcinoma cells, initiate the digestion of poly adenosine diphosphate-ribose polymerase (PARP), and significantly inhibit the expression of anti-apoptotic protein Bcl-2; meanwhile, curcumin can also inhibit the secretion of thyroid carcinoma cell matrix metalloproteinase-9 and the adhesion to extracellular matrix. Above results show that curcumin has good intervention effect on various links of proliferation, migration, and adhesion of thyroid carcinoma cells, and is applicable to the preparation of medicaments for treating thyroid carcinoma.

The invention discloses a PCR (Polymerase Chain Reaction) specific primer and a kit for detecting a thyroid cancer metastasis associated gene, and a using method of the kit. The thyroid cancer metastasis associated gene related to PCR specific primer and the kit, which are independently researched and developed and are based on a high throughput sequencing technology, for detecting the thyroid cancer metastasis associated gene and the using method of the kit is subjected to sample validation, the PCR specific primer, the kit and the using method can be used for detecting a mutation situation of the thyroid cancer metastasis associated gene, a detection result can be used as an intermediate result together with other detecting results for judging whether cancer cells are metastasized or notor the cancer cells have the possibility of metastasis or recurrence, and an important significance in treatment and prognosis of thyroid cancer is obtained; in addition, limit of a traditional detecting technology is broken through by utilizing the high throughput sequencing technology, the detection sensitivity is increased, and even low-abundance mutant genes can also be detected, so that theimportant significance in aided prediction on spreading and recurrence of thyroid cancer cells is obtained.

The invention relates to a novel use of sanguinarine chloride and especially relates to a use of sanguinarine chloride in preparation of a drug for treating a thyroid cancer. In-vivo and in-vitro thyroid cancer experiments prove that sanguinarine chloride has effects of inhibiting or killing thyroid cancer cells, has human papilloma thyroid cancer cells IHH-4 and human anaplastic thyroid cancer cells ASH-3 growth IC50 values of 1.44 micromoles per liter and 2.62 micromoles per liter, and reduces a survival rate of thyroid cancer cells to less than 10%. A nude-mice in-vivo anti-cancer experiment proves that sanguinarine chloride has a transplantation tumor inhibition ratio of 80.81%.

The present invention relates to a health-care tea product, in particular to a health-care tea product based on d-borneol and a preparation method thereof. The health-care tea product comprises the following components and the grams of each component are as follows: D-borneol Vitamin K: 100~145g; Ascorbic acid: 85~100g; Citric acid: 60~80g; Pectin: 95~115g; Carotene: 76~90g; Flavonoids: 20~23g; Vitamin E: 30-35g; selenium 12-18g; the present invention not only has the functions of refreshing the mind, calming the mind and calming the nerves, but also induces the apoptosis of nasopharyngeal carcinoma, lung cancer, thyroid cancer and breast cancer cells; relieves chest tightness, angina pectoris and headache, and prevents aging Dementia; detoxification and beautification, directly into the heart and lungs, so that poisonous gas and turbid gas are scattered outside the body, promoting blood circulation and acne, and improving meridians; preventing respiratory diseases; can relieve pain, relieve itching, reduce swelling, reduce phlegm, remove acne, promote muscle growth, and inhibit bacteria and other functions.

The invention discloses a vector and a preparation for knocking down a human CBS gene as well as a preparation method and application thereof, and relates to the technical field of biological pharmacy. The preparation method of the vector comprises the following steps: designing a primer for PCR amplification of a target gene according to a human CBS gene sequence, and the specific sequence is as shown in SEQ ID NO.1; restriction sites BamH I and Hind III in the GV102 vector are digested to form a linearized GV102 vector, and the sequence of the GV102 vector is hU6-MCS-CMV-GFP-SV40-Neomycin; and connecting the products obtained in the previous two steps to construct a GV102-CBS vector. The vector prepared by the invention can obviously inhibit the expression of human CBS genes, achieve the purposes of inhibiting the growth of human thyroid cancer cells and reducing the migration rate of the cancer cells, and can be used for preparing a preparation for treating the human thyroid cancer.

The invention discloses a poorly differentiated thyroid cancer cell line PDTC-1 and applications thereof. The cell line is a poorly differentiated thyroid cancer cell line, and the accession number thereof is CGMCC No. 4939. The present invention establishes a poorly differentiated thyroid carcinoma cell line, successfully establishes a nude-mouse transplanted tumor model by using the cell line, provides a screenable cell line for the study of thyroid cancer cytology, and the cell line can be used for establishing important models for screening thyroid cancer-sensitive chemotherapy drugs. On the basis of the present invention, differences of differentiated, poorly differentiated and undifferentiated thyroid cancers can be studied from the genetic level and the protein level, having important meaning for elucidating the generating mechanism and finding therapeutic targets of the thyroid cancer. The cell line of the present invention provides a platform for the study of thyroid cancer evolution and biological characteristics of poorly differentiated cancers, and is conducive to the in-depth study of pathogenesis, metastasis and recurrence of thyroid cancer.

The invention belongs to the technical field of pharmacy, and provides triptolide derivatives, and a preparation method and applications thereof. The structural formula of triptolide derivatives is represented in the description, and R represents an amine ring compound group, more specifically, a cyclohexane group, a morpholine group, or an aniline group. The preparation method comprises followingsteps: taking triptolide as the raw material, adding an amine ring reagent and a catalyst into triptolide, wherein the mole ratio of triptolide to the amine ring reagent is 1:1-6, and the mole ratioof triptolide to the catalyst is 1:0.1-0.4; carrying out reactions for 24-48 hours in the absence of solvent; after reactions, carrying out a post treatment: washing the reaction liquid by ethyl acetate, then washing the ethyl acetate phase by deionized water for many times, drying, dehydrating, and drying; and purifying triptolide derivates: adopting an adsorbent as a stationary phase to carry out separation and purification, and recovering and drying the eluent to obtain triptolide derivates. The triptolide derivates can inhibit thyroid cancer cells, human prostatic cancer cells, and colon cancer cells.

It is found for the first time that down-regulation is conducted in thyroid cancer tissues, down-regulation is more obvious in thyroid cancer tissues with lymph node metastasis, MAPK8IP1P2 down-regulation indicates poor prognosis of thyroid cancer patients, and overexpression of MAPK8IP1P2 can inhibit in-vivo tumorigenesis of thyroid cancer cells. Based on the new discovery, the MAPK8IP1P2 can beused for diagnosing whether a subject suffers from thyroid cancer or not, lymph node metastasis of thyroid cancer and survival prognosis, thyroid cancer tumorigenesis is inhibited through the medicinefor overexpression of the MAPK8IP1P2, and a new strategy is provided for diagnosis, prognosis and treatment of the thyroid cancer.

The invention belongs to the field of biological medicine research, and particularly relates to application of a human SHCBP1 gene used as a target in preparing a thyroid cancer treatment medicine orpreparing a thyroid cancer diagnosis medicine. Through the broad and deep research, the invention discovers that after the expression of the human SHCBP1 gene is down-regulated by adopting an RNAi method, the multiplication of thyroid cancer cells can be effectively inhibited, the cell apoptosis is promoted, and the growth process of thyroid cancer can be effectively controlled. The siRNA or a nucleic acid building body and a slow virus containing the siRNA can specifically inhibit a multiplication capacity of the thyroid cancer cells, inhibit a tumor formation capacity of the thyroid cancer cells in a human body, promote the thyroid cancer cell apoptosis, inhibit the cloning of the thyroid cancer cells, inhibit a thyroid cancer cell metastasis capacity, inhibit a thyroid cancer cell transfer capacity and change the period distribution of the thyroid cancer cells so as to treat the thyroid cancer, so that a new direction is opened for thyroid cancer treatment.

The invention belongs to the field of traditional Chinese medicines, and particularly discloses a traditional Chinese medicine composition for treating thyroid cancer and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following nine raw medicinal materials: astragalus membranaceus, bighead atractylodes rhizome, poria cocos, white paeony root, prepared arisaema consanguineum schott, thunberg fritillary bulb, pinellia ternate, oroxylum indicum and selfheal, and has the effects of invigorating spleen and replenishing qi, eliminating dampness and phlegm, and softening hardness to dissipate stagnation. Pharmacodynamic experiment results show that the traditional Chinese medicine composition disclosed by the invention can obviously inhibit the growth of human thyroid cancer tumors in nude mice bearing tumors and obviously inhibit the proliferation of thyroid cancer cells in vitro, has an exact treatment effect on thyroid cancer, and provides a new clinical medication choice for patients.

The invention relates to the application of valproate and salt-induced redifferentiation combined with <131> iodine thereof in treating poor differentiation / dedifferentiation thyroid cancer, belonging to the pharmaceutical field, in particular to the pharmaceutical use of the valproate and salt thereof. Sulfonyl rhodamine B (SRB) dyeing analysis is adopted to detect influence of the valproate and the salt thereof on cell proliferation of follicular thyroid cancer cell strain FTC-133 and cell proliferation of papillary thyroid cancer cell strain K1; RT-PCR detects NIS mRNA expression in FTC-133 and K1 cells induced by the valproate and the salt thereof, and variation of iodine uptake of thyroid cancer cells after induced is analyzed; the result shows that the valproate and the salt thereof can obviously inhibit the proliferation of the thyroid cancer cells, and the inhibition rate is also increased along with increase of concentration; the NIS mRNA expression of FTC-133 and the NIS mRNA expression of K1 are both increased after being induced, and radioactive <131> iodine uptake of cancer cells is also increased; the poor differentiation / dedifferentiation thyroid cancer can select radioactive <131> iodine to carry out treatment because of the radioactive <131> iodine uptake increase of the cancer cells.

A pharmaceutical composition containing a tyrosine kinase activity inhibitor as an active ingredient may increase the expression of sodium iodide symporter in thyroid cancer cells, thereby promoting iodine uptake and killing thyroid cancer cells. Thus, the composition may be useful for the treatment of thyroid cancer.

The present disclosure relates to a sodium iodide symporter (NIS)-repressor binding sites (NRBS) consensus sequence consisting of a DNA molecule having the sequence 5′-T / C(G / A)GCCT(T / C)A(G / A)TTTCCCCA(T / C)CTGT-3′(the “consensus NRBS”). The disclosure further relates to methods of restoring iodide transport in dedifferentiated thyroid cancer cells by interfering with formation or function of the NIS repressor.

The invention discloses a PCR-specific primer, a kit and a use method thereof for detecting genes related to metastasis of thyroid cancer. The high-throughput sequencing technology-based PCR-specific primers for the detection of thyroid cancer metastasis-related genes independently developed by the present invention, the kit and the use method involved in the thyroid cancer metastasis-related genes have been verified by samples and can be used to detect thyroid cancer The mutation status of metastasis-related genes, the test result can be used as an intermediate result together with other test results to determine whether cancer cells have metastasized or whether there is a possibility of metastasis or recurrence, which is of great significance for the treatment and prognosis of thyroid cancer. Moreover, the present invention uses high-throughput gene sequencing technology to break through the limitations of traditional detection technology, improves detection sensitivity, and can detect even low-abundance mutated genes, thereby helping to predict the possibility of proliferation and recurrence of thyroid cancer cells. Significance.

The invention belongs to the technical field of artificial cultivation of edible fungi, particularly relates to an artificially cultivated phellinus igniarius sporocarp extract for treating thyroid cancer, and further discloses a preparation method of the artificially cultivated phellinus igniarius sporocarp extract. The artificially cultivated phellinus igniarius sporocarp extract for treating the thyroid cancer is obtained by taking phellinus igniarius sporocarp as a raw material for carrying out water body and alcohol precipitation extraction, the obtained extract has the effects of supporting body resistance and promoting immune functions, has an obvious inhibiting effect on in-vivo transplantation of nude mice with human thyroid cancer, can obviously inhibit proliferation of thyroid cancer cells in vitro at the same time, has a good thyroid cancer treatment effect, can relieve the pain of a tumor patient, prolongs the lifetime, improves the life quality of the patient, and bringsa new candidate medicine for treating the thyroid cancer to clinical application, and the extract is a natural extract, and has the advantages of being high in medication safety and low in toxic and side effects.

The invention discloses an oncologic preparation for treating thyroid cancer. The oncologic preparation is prepared from the following raw materials in parts by weight: 13-16 parts of celosia cristata, 13-17 parts of disporum cantoniense rhizome, 11-15 parts of dendrobium jenkinsii, 9-14 parts of swertia yunnanensis, 8-12 parts of semiaquilegia adoxoides, 11-16 parts of rose mallow root, 7-12 parts of berchemia lineata, 9-14 parts of Korean raspberry root, 9-13 parts of chamaenerion angustifolium rhizome, 7-12 parts of tangerine pith, 9-15 parts of acorus tatarinowii and 7-13 parts of ainsliaea latifolia. The oncologic preparation, which is prepared by reasonable and scientific compatibility of multiple Chinese medicinal herbs supplementing each other on effects, has the effects of activating blood circulation and stimulating meridians, reducing swelling and resolving mass, and invigorating spleen to remove phlem, is capable of effectively controling transfer and diffusion of thyroid cancer cells, and has a good effect of treating thyroid cancer and quick response.

The invention belongs to the field of tumor molecular biology and particularly relates to application of an XPR1 inhibitor in preparation of a product for inhibiting migration and / or proliferation of thyroid cancer cells. The invention finds that the expression of an XPR1 gene in the thyroid cancer cells is obviously higher than that of normal thyroid cells, and the influence of the XPR1 gene on the migration and proliferation capacity of the thyroid cancer cells is verified through a CCK-8 experiment, a colony formation experiment, a Transwell migration experiment, a Matrigel invasion experiment, a flow cytometry, a cell apoptosis experiment and a Western blot experiment. The invention finds that the migration and proliferation capacity of the thyroid cancer cells can be effectively lowered by knocking down the expression of the XPR1 gene.

The invention provides an application of piRNA-26131 in preparation of a thyroid cancer diagnostic and prognostic marker. The invention also provides an application of the piRNA-26131 in preparation of a kit for diagnosing a thyroid cancer or judging whether the thyroid cancer recurs. In addition, the invention provides a method for detecting the piRNA-26131 in thyroid cancer tissue or blood for non-diagnostic and therapeutic purposes. After overexpression or knockdown of the piRNA-26131, the proliferation and invasion metastasis ability of thyroid cancer cells are significantly enhanced or weakened, patients with piRNA-26131 high expression have high probability of recurrence, so that the piRNA-26131 can be used as the blood screen molecular marker for early screening and tumor recurrenceindicators of the thyroid cancer patients, and has great significance and application prospects.

The invention belongs to the field of biomedicines and relates to an application of miR-125b or a mimic or an accelerant thereof in preparation of a chemotherapeutic drug synergist. Studies find thatthe expression of Foxp3 is up-regulated when miR-125b is down-regulated in a thyroid cancer tissue sample. Besides, miR-125b can be combined with 3'UTR of miR-125b to directly act on Foxp3 and inhibitexpression of Foxp3, and therefore, the negative correlation between miR-125b and Foxp3 is disclosed. Overexpressed miR-125b remarkably increases the sensitivity of sensitized thyroid cancer cells totreatment with a chemotherapeutic agent through induction, and in-vitro and in-vivo autophagy is performed through an Atg7 way. In general, miR-125b negatively controls autophagy of an Foxp3 promotednew mechanism and enhances the curative efficacy of the chemotherapeutic agent for thyroid cancer, and it indicates that miR-125b has a remarkable treatment significance in chemotherapy of the thyroid cancer.